Previous close | 201.26 |
Open | 203.70 |
Bid | 201.38 x 1000 |
Ask | 201.43 x 900 |
Day's range | 198.02 - 204.68 |
52-week range | 117.06 - 204.68 |
Volume | 5,464,363 |
Avg. volume | 4,418,374 |
Market cap | 193.21B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 33.05 |
EPS (TTM) | 6.11 |
Earnings date | 29 Jan 2021 |
Forward dividend & yield | 3.40 (1.69%) |
Ex-dividend date | 11 Feb 2021 |
1y target est | 194.47 |
Results of a clinical trial suggest pre-emptive treatment with bamlanivimab can prevent COVID-19 from spreading through nursing homes.
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.